Zobrazeno 1 - 10
of 36
pro vyhledávání: '"SL de Haas"'
Autor:
K. Dadswell, Sandra M. Swain, Daniel Eiger, L. De La Cruz Merino, SL de Haas, Ramon Colomer, J-M Ferrero, Michael S. Ewer, S. Sarkar, Mark Verrill, Eleonora Restuccia, Chau T. Dang, Suzette Delaloge
Publikováno v:
Annals of Oncology. 32:S38-S39
Autor:
I. Melero, G Lewis Phillips, Sandra M. Swain, Carlos H. Barrios, Hervé Bonnefoi, EP Winer, L. Gianni, SL de Haas, M. Toi, S-A. Im, Thomas Boulet, Charles M. Perou, Paul Anthony Ellis, Ian E. Krop, C. Lambertini, Nadia Harbeck, Chunyan Song, Julie R. Gralow, Otto Metzger, Fraser Symmans
Publikováno v:
Annals of Oncology. 32:S37-S38
Autor:
V Lopez Valverde, H-J Helms, S Hurvitz, M. Martin, Astrid Kiermaier, Michael F. Press, DJ Slamon, SL de Haas, G Lewis Phillips, Aleix Prat
Publikováno v:
Cancer Research. 78:PD3-06
Introduction: Previous studies have shown that HER2+ breast cancer is biologically heterogenous and intrinsic subtypes can be identified (luminal A, luminal B, HER2-enriched [HER2-E] and basal-like). HER2-E predominates and is associated with higher
Autor:
Helmut Forstbauer, Claudia Schumacher, E-M. Grischke, Bahriye Aktas, O Gluz, Rachel Wuerstlein, Cornelia Kolberg-Liedtke, SL de Haas, Michael Braun, Claudia Biehl, R Kates, Matthias Christgen, Wolfram Malter, Hans-Heinrich Kreipe, Regula Deurloo, Nadia Harbeck, J. Tio, S. Kuemmel, U. Nitz, C. Eulenburg zu
Publikováno v:
Annals of Oncology. 32:S1285
Autor:
J. Potenberg, R Kates, C Matthias, H.H. Kreipe, Stefan Kraemer, Anke Kleine-Tebbe, Bahriye Aktas, Doris Augustin, Rachel Wuerstlein, S Kümmel, Claudia Schumacher, O Gluz, Michael Braun, Nadia Harbeck, J. Tio, Helmut Forstbauer, U. Nitz, SL de Haas, Cornelia Liedtke, Regula Deurloo, E-M Grischke, Johannes Schumacher
Publikováno v:
Cancer Research. 77:P1-09
Background: Immune and apoptosis biomarkers are potential prognostic/predictive markers in HER2+ EBC. High PD-L1 expression was shown to be predictive for lower pCR after chemotherapy+trastuzumab+/-pertuzumab, particularly in HER2+, ER- disease. Yet,
Autor:
José A. García-Sáenz, Monika Patre, J. Xu, Jenny C. Chang, P. Fumoleau, SL de Haas, Miguel Martín, S. A. Limentani, Alexander Strasak, Joan Albanell, J. A. Dewar, Mario Campone
Publikováno v:
Annals of Oncology. 27:1249-1256
Background Trastuzumab emtansine (T-DM1) exhibited enhanced antitumor activity when combined with docetaxel or pertuzumab in preclinical studies. This phase Ib/IIa study assessed the feasibility of T-DM1 + docetaxel in patients with human epidermal g
Autor:
S.-B. Kim, Monika Patre, Hongfang Liu, SL de Haas, Cristina Saura, Mark Beresford, M. De Laurentiis, S.-A. Im, Francisco J. Esteva, Leisha A. Emens, Yulei Wang, Aruna Mani, Jigna Shah, Sherene Loi
Publikováno v:
Annals of Oncology. 30:v104
Background T-DM1 is indicated for the treatment of HER2+ metastatic BC previously treated with trastuzumab and a taxane, separately or in combination. Atezo is an anti-PD-L1 antibody that inhibits PD-L1 binding to PD-1 and B7.1 thereby restoring anti
Autor:
S-B Kim, Francisco J. Esteva, Yunxiang Wang, M. De Laurentiis, Cristina Saura, Leisha A. Emens, Mark Beresford, SL de Haas, Sherene Loi, S-A Im, Monika Patre, Hongfang Liu, Aruna Mani
Publikováno v:
Cancer Research. 79:PD3-01
Background T-DM1 has improved PFS and OS in HER2+ advanced BC patients (pts) who previously progressed on trastuzumab and a taxane (Verma NEJM 2012). Preclinical data show that atezo (anti–PD-L1) inhibits PD-L1 binding to PD-1 and B7.1 to restore a
Autor:
Michael F. Press, DJ Slamon, J. Xu, M. Martin, S Hurvitz, H-J Helms, G Lewis Phillips, Astrid Kiermaier, SL de Haas
Publikováno v:
Cancer Research. 77:P6-07
Introduction KRISTINE (NCT02131064) is an open-label, phase 3 study of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) vs docetaxel + carboplatin + trastuzumab + pertuzumab (TCH+P) in pts with HER2+ EBC (all pts, Table). In exploratory analy
Autor:
J. D. Boot, Adam F. Cohen, A. Denker, Zuzana Diamant, M De Smet, T. Leathem, J.M.A. van Gerven, John A. Wagner, Rik C. Schoemaker, D. Miller, SL de Haas, M.B.A. Van Doorn
Publikováno v:
Pulmonary Pharmacology & Therapeutics. 21:573-577
Background MK-0873 is a novel selective phosphodiesterase-4 inhibitor, which has been in development for the treatment of chronic obstructive pulmonary disease (COPD). In this indication, theophylline is still an important treatment, despite its rela